$1.43
8.92% yesterday
Nasdaq, Nov 15, 10:04 pm CET
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Fortress Biotech, Inc. Stock price

$1.43
-0.29 16.86% 1M
-0.31 17.82% 6M
-1.58 52.49% YTD
+0.05 3.62% 1Y
-48.97 97.16% 3Y
-25.27 94.64% 5Y
-24.52 94.49% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.14 8.92%
ISIN
US34960Q1094
Symbol
FBIO
Sector
Industry

Key metrics

Market capitalization $39.42m
Enterprise Value $18.20m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 0.29
P/S ratio (TTM) P/S ratio 0.63
P/B ratio (TTM) P/B ratio 1.86
Revenue growth (TTM) Revenue growth -22.81%
Revenue (TTM) Revenue $62.50m
EBIT (operating result TTM) EBIT $-103.46m
Cash position $58.85m
EPS (TTM) EPS $-3.27
P/E forward negative
P/S forward 0.53
EV/Sales forward 0.28
Short interest 11.50%
Show more

Is Fortress Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Fortress Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Fortress Biotech, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Fortress Biotech, Inc. forecast:

Buy
100%

Financial data from Fortress Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
63 63
23% 23%
100%
- Direct Costs - -
-
-
37 37
27% 27%
59%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 61 61
52% 52%
98%
- -
-
-
- Depreciation and Amortization 7.37 7.37
7% 7%
12%
EBIT (Operating Income) EBIT -103 -103
41% 41%
-166%
Net Profit -49 -49
38% 38%
-78%

In millions USD.

Don't miss a Thing! We will send you all news about Fortress Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fortress Biotech, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and...
Neutral
GlobeNewsWire
3 days ago
Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024, and recent corporate updates.
Neutral
GlobeNewsWire
3 days ago
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025
More Fortress Biotech, Inc. News

Company Profile

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The company was founded on June 28, 2006 and is headquartered in New York, NY.

Head office United States
CEO Lindsay Rosenwald
Employees 186
Founded 2006
Website www.fortressbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today